A Prospective, Open Label Study of CERtican in KIdney Transplantation

Kidney Transplant Clinical Trial

— CERKI  

Official title:

A Prospective, Open-label Study to Assess Safety of Certican in Kidney Transplant Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01594268
• Other study ID #: CRAD001AKR10
• Status: Completed
• Phase: Phase 4
• First received: May 4, 2012
• Last updated: March 17, 2017
• Start date: March 2012
• Est. completion date: October 2013

Study information

• Verified date: March 2017
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A prospective, open label study of CERtican in KIdney transplantation

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria: (Each patient must meet all of the following criteria.)

1. Males and females aged 20-65 years inclusive (in Korean age) who is scheduled to receive a primary kidney transplant.

2. Patients who received explanation of the study overview and signed on the informed consent form of this study.

3. de novo patients who are going to receive a kidney transplant from a deceased (cold ischemic time (CIT) < 36 hours), living unrelated or related donor

Exclusion criteria (Any patient who meets any of the following criteria will not be able to participate in the study.)

1. Multi-organ transplant recipients (e.g. simultaneous kidney-pancreas transplant) or patients who previously received an organ transplant other than a kidney transplant

2. Patients who are scheduled to receive a kidney transplant from a zero-antigen mismatched donor, bilateral kidney donor, a non-heart beating donor or a donor aged over 60 years

3. Patients who should avoid potential exposure to everolimus due to acute or chronic severe allergy treatment or patients who have hypersensitivity to everolimus and drugs of similar chemical classes (e.g. macrolides)

4. Class 1 PRA>30% by CDC-based assay or Class 1 PRA>50% by flow cytometry or EIA

5. Recipients of a kidney from a ABO-incompatible live-donor or T-cell cross matching-positive donor

6. Thrombocytopenia<75,000/mm3, absolute neutrophil count<1,500/mm3, and/or leukopenia<4,000/mm3

7. Severe hypercholesterolemia (350mg/dl) or hypertriglyceridemia (>500mg/dl) (However, patients with controlled hyperlipidemia are eligible for the study.)

8. Use of other investigational drugs for 30 days before enrollment in the study

9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years before enrollment in the study, regardless of whether there is evidence of local recurrence or metastases

10. Pregnant or nursing women, and women of child-bearing potential who have a plan to be pregnant or do not consent to select an appropriate method of birth control (e.g. oral contraceptives, hormone implant, IUD, diaphragm barrier, condom, abstinence, etc.) (women of child-bearing potential means women less than 2 years post-menopausal or not having hysterectomy or surgical management, i.e. bilateral tubal ligation or bilateral oophorectomy)

11. Presence of surgery or medical condition (except for current transplant) which may change absorption, distribution, metabolism, and excretion of the investigational product at the investigator's discretion and/or severe diarrhea, active gastrointestinal disease or uncontrolled diabetes

12. Patients who are HIV-, HCV-, and HBV positive

13. Recipients of an organ from a donor who is HBsAg-, HCV-, and HIV-positive

14. Evidence of drug or alcohol abuse

15. Severe restrictive or obstructive pulmonary disease

16. Patients with severe liver disease (AST, ALT or total bilirubin>2.5 times ULN including abnormal liver function test)

17. Patients with severe systemic infection requiring continuous therapy which may influence the objectives of the study at the investigator's discretion

18. Patients in whom continuous treatment may lead to clinically serious infection at the investigator's discretion or patients with other severe surgery complications or problems with continuous wound treatment

19. Patients who have a genetic problem including galactose intolerance, lapp lactase deficiency, and glucose-galactose malabsorption

Related Conditions & MeSH terms

• Kidney Transplant

Intervention

Drug:
• Everolimus
A prospective, open-label study to assess safety of Certican in kidney transplant patients

Locations

Country	Name	City	State
Korea, Republic of	Novartis Investigative Site	Seoul	Korea
Korea, Republic of	Novartis Investigative Site	Seoul
Korea, Republic of	Novartis Investigative Site	Seoul
Korea, Republic of	Novartis Investigative Site	Suwon

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with serious adverse events	frequency of serious adverse event	12 weeks

External Links

•   Clinical Trial Results for CRAD001AKR10 at Novartis Clinical Trials